Guidance for the adjustment of FRAX according to the dose of glucocorticoids

Author： Kanis J.   Johansson H.   Oden A.   McCloskey E.  

Publisher： Springer Publishing Company

ISSN： 0937-941X

Source： Osteoporosis International, Vol.22, Iss.3, 2011-03, pp. : 809-816

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

How close are we to individual analgesic adjustment according to a patient’s genotype?

By Samer Caroline Flora   Dayer Pierre   Desmeules Jules Alexandre  

Personalized Medicine, Vol. 8, Iss. 3, 2011-05 ,pp. : 289-292

Future Medicine

Access to resources Recommend Favorite

Development and use of FRAX® in osteoporosis

By Kanis J.   McCloskey E.   Johansson H.   Oden A.   Ström O.   Borgström F.  

Osteoporosis International, Vol. 21, Iss. 2, 2010-06 ,pp. : 407-413

Springer Publishing Company

Access to resources Recommend Favorite

Pitfalls in the external validation of FRAX

By Kanis J.  

Osteoporosis International, Vol. 23, Iss. 2, 2012-02 ,pp. : 423-431

Springer Publishing Company

Access to resources Recommend Favorite

A single dose of zoledronic acid reverses the deleterious effects of glucocorticoids on titanium implant osseointegration

By Carvas J.   Pereira R.   Caparbo V.   Fuller P.   Silveira C.   Lima L.   Bonfa E.   Mello S.  

Osteoporosis International, Vol. 21, Iss. 10, 2010-10 ,pp. : 1723-1729

Springer Publishing Company

Access to resources Recommend Favorite

A case of hypocomplementaemic urticarial vasculitis with cardiac valve involvement successfully treated with cyclophosphamide and high‐dose glucocorticoids

By  

INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (ELECTRONIC), Vol. 20, Iss. 11, 2017-11 ,pp. : 1850-1852

John Wiley & Sons Inc

Access to resources Recommend Favorite